BioMarin Officially Closes Amicus Therapeutics Acquisition
BMRN is trading near its 52-week low of $50.76 (6.3% above the low).
Summary
BioMarin Pharmaceutical Inc. has officially completed its acquisition of Amicus Therapeutics. This finalizes the significant transaction, which was initially detailed in BioMarin's February 10-K filing and received final regulatory clearance just days ago, as announced in an April 23rd 8-K and news report. The completion removes any remaining uncertainty regarding the deal, allowing BioMarin to proceed with the integration of Amicus's assets and operations. Traders will now focus on the combined entity's updated financial outlook, integration progress, and the potential for new product pipeline developments from the acquired assets.
At the time of this announcement, BMRN was trading at $53.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $50.76 to $66.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.